SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegatio ...

Core Viewpoint - A class action lawsuit has been filed against Reddit, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Financial Performance - On May 1, 2025, Reddit reported its financial results for Q1 2025, marking its third consecutive quarter of declining daily active user growth [3]. - Following the Q1 report, Reddit's stock price fell by $4.96 per share, or 4.18%, closing at $113.83 on May 2, 2025 [3]. Analyst Downgrades - On May 19, 2025, Wells Fargo analysts downgraded Reddit's stock, citing concerns over new AI features implemented by Google Search that could disrupt user traffic, resulting in a stock price drop of $5.24 per share, or 4.63%, to close at $107.99 on May 10, 2025 [4]. - On May 21, 2025, Baird analysts also downgraded Reddit's stock for similar reasons, leading to a further decline of $9.79 per share, or 9.27%, closing at $95.85 on May 21, 2025 [5].

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DoubleVerify Holdings, Inc. ("DoubleVerify Holdings, Inc." or the "Company") (NYSE: DV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DoubleVerify Holdings, Inc. investors who were adversely affected by alleged securities fraud between November 10, 2023 and February 27, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

Core Viewpoint - A class action securities lawsuit has been filed against Rocket Companies, Inc. due to alleged securities fraud that occurred between March 29, 2021, and April 1, 2021 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Rocket's gain on sale margins were contracting at the highest rate in two years due to increased competition among mortgage lenders and a shift towards lower margin segments [2]. - It is alleged that Rocket was engaged in a price war with competitors, further compressing margins in its Partner Network operating segment [2]. - The complaint states that adverse trends were accelerating, with gain on sale margins expected to plummet by at least 140 basis points in the first half of 2021 [2]. - The favorable market conditions that previously allowed Rocket to achieve high gain on sale margins had disappeared, returning to levels not seen since Q1 2019 [2]. - The company's gain-on-sale margins had fallen materially below recent historical averages, contradicting positive statements made by the defendants about the company's operations and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until July 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - Altimmune, Inc. is under investigation for potential securities fraud following the release of mixed results from a clinical trial, which led to a significant drop in its stock price [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Altimmune regarding possible securities fraud or unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]. Group 2: Clinical Trial Results and Market Reaction - On June 26, 2025, Altimmune announced "topline results" from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), describing the results as "positive" [2]. - The trial reported fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with the differences not being statistically significant [2]. - Following the announcement, Altimmune's stock price fell by $4.10, or 53.18%, closing at $3.61 per share on the same day [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant investor losses [2][4][12]. Group 1: Company Overview - Red Cat Holdings, Inc. (NASDAQ: RCAT) is involved in the production of small unmanned aerial systems (sUAS) for military applications, specifically under the U.S. Army's Short Range Reconnaissance Program [5][11]. - The company announced in March 2022 that it was selected to compete in the U.S. Army's SRR Program, which is aimed at providing portable sUAS to Army platoons [5]. Group 2: Allegations and Misleading Statements - The complaint against Red Cat alleges that the company overstated the production capacity of its Salt Lake City facility and the overall value of the SRR Contract, leading to materially false and misleading public statements [4][6]. - During a conference call on July 27, 2023, Red Cat revealed that the Salt Lake City facility could only produce 100 drones per month, contrary to earlier claims of thousands, and that the facility was still under construction [7]. - Following these disclosures, Red Cat's stock price fell by 8.93% to close at $1.02 per share on July 28, 2023 [8]. Group 3: Financial Performance and Stock Impact - In the first quarter of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [9]. - After announcing a pause in manufacturing due to retooling the Salt Lake City facility, Red Cat's stock price dropped by 25.32% over two trading sessions, closing at $2.36 per share on September 25, 2024 [10]. - A report published by Kerrisdale Capital on January 16, 2025, alleged that the SRR Contract was worth only $20 million to $25 million, significantly lower than previously stated, leading to a further stock price decline of 21.54% [12][13]. Group 4: Legal Proceedings - Investors who suffered losses exceeding $50,000 in Red Cat between March 18, 2022, and January 15, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Red Cat is July 21, 2025 [2].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly violating federal securities laws by making false and misleading statements regarding the company's business and operations [1][2]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Hims & Hers made false statements about a collaboration with Novo Nordisk that would ensure continued access to the weight-loss drug Wegovy for its subscribers [2]. - It is alleged that Hims & Hers misrepresented that Novo approved its offerings of compounded semaglutide products under a "personalization" exception [2]. - The suit contends that Hims & Hers falsely indicated that branded Wegovy would be available alongside compounded semaglutide options, thereby misleading investors about user choice [2]. - Positive statements regarding the partnership with Novo and ongoing access to Wegovy were also allegedly made, which contributed to the decline in the company's stock value [2]. Group 2: Legal Proceedings - The lawsuit was filed in the Northern District of California and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05321 (N.D. Cal.) [3]. - The class action is on behalf of all individuals who purchased Hims & Hers common stock between April 29, 2025, and June 23, 2025 [3]. Group 3: Class Member Information - Investors who acquired Hims & Hers stock during the specified class period may seek to be appointed as lead plaintiffs, with a deadline to do so by August 25, 2025 [4]. - It is noted that investors do not need to be lead plaintiffs to participate in any potential recovery from the lawsuit [5].

Core Viewpoint - A securities class action lawsuit has been filed against Reddit, Inc. for allegedly making false and misleading statements regarding user traffic and advertising revenues during the specified class period [1][2]. Group 1: Allegations Against Reddit - The lawsuit claims that Reddit's management failed to disclose significant changes in Google Search's algorithm that negatively impacted user traffic to Reddit [2]. - It is alleged that the increase in search queries for "Reddit" was due to users finding answers directly on Google, rather than intending to visit Reddit [2]. - The complaint states that these factors led to a dramatic reduction in traffic that Reddit could not mitigate in the short term, undermining the company's outlook on user rates and advertising revenues [2]. Group 2: Legal Process for Investors - Investors who suffered losses during the class period can seek to be appointed as lead plaintiffs by August 18, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel to direct the litigation [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ: GOCO) complied with federal securities laws. On May 1, 2025, the Department of Justice filed a complaint against GoHealth and others alleging that the Company, among other things, “knowingly entered into unlawful agreements to present false or fraudulent claims to the Government and performed acts in furtherance of this conspiracy.” Following this news, the price of ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE: CIVI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Civitas you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/civitas-resources-inc. Investors have until July 1, 2025, to ask the Court to be appointe ...